Herpes simplex
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
Herpes simplex molomong.
Herpes simplex ― Tšoaetso ea Herpes simplex menoaneng e atile haholo ho bana ba banyenyane ho feta ho batho ba baholo.
References
Ts'oaetso ea HSV-1 e tsoela pele ka tšoaetso ea mantlha ea lisele tsa epithelial, e lateloa ke latency, haholo-holo li-neurone, le ho tsosolosa. HSV-1 hangata e baka ho foqoha ha vesicular ho qala le ho ipheta khafetsa, haholo-holo molomong le molomong oa setho sa botona. Lipontšo tsa eona li tloha ho orolabial herpes ho ea ho maemo a fapaneng a kang herpetic folliculitis, tšoaetso ea letlalo, ho ameha ha mahlo, le linyeoe tse matla tse kang herpes encephalitis. Kalafo ea antiviral e thusa ho laola tšoaetso ea HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 2 (HSV-2) ke ts'oaetso e atileng, e amang hoo e ka bang 22% ea batho ba baholo ba lilemo li 12 ho ea holimo, e leng kakaretso ea batho ba baholo ba limilione tse 45 United States. Le hoja HSV-1 e atisa ho baka liso tsa molomo, e ka boela ea baka maqeba a litho tsa botona kapa botšehali. Leha ho le joalo, ha bakuli ba e-na le maqeba a litho tsa botona kapa botšehali, HSV-2 hangata ke eona ntho e amehang haholo. Matšoao a ho qhoma ha HSV-2 hangata ha a hlaka, joalo ka ho hlohlona le ho teneha ha litho tsa botona kapa botšehali, tse ka liehisang tlhahlobo le kalafo. Ho lieha hona ho ka etsa hore tšoaetso e tsoele pele ho batho ba se nang tšoaetso.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus (HSV) hangata e baka mafu a kang genital herpes le sefuba ho bacha le batho ba baholo. Ha HSV e tšoaetsa lesea nakong ea libeke tse 4-6 tsa pele tsa bophelo, e ka fella ka ho kula ho matla le liphello tse tebileng. Ho hlahloba ka potlako tšoaetso ea HSV ea lesea ho bohlokoa ho thibela lefu lena hore le se ke la mpefala, ho thibela mathata a methapo (esita le lefu) .
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex tšoaetso e atile haholo 'me e ka fetisoa ho tloha ho bakhachane ho ea ho masea a bona. Kokoana-hloko ena e ka baka mathata a tebileng a bophelo bo botle kapa lefu ho masea a sa tsoa tsoaloa. Le hoja e sa tloaelehe nakong ea bokhachane ka boeona, hangata e etsahala nakong ea pelehi. Kotsi e kholo haholo haeba 'm'e a ka tšoaetsoa nakong ea bokhachane. Leha ho le joalo, kotsi ena e ka fokotsoa ka ho sebelisa lithethefatsi tse thibelang kokoana-hloko kapa ho khetha karolo ea C maemong a itseng.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Herpes simplex virus (HSV) mefuta ea 1 le ea 2 e tšoaetsa batho ba bangata lefatšeng ka bophara. Hangata, kokoana-hloko eo e lula e khutsitse liseleng tsa methapo ka mor’a hore e tšoae letlalong, empa e ka boela ea sebetsa hamorao, ea baka liso tse batang. Ka linako tse ling, e lebisa mathateng a matla joalo ka ts'oaetso ea mahlo, ho ruruha boko, kapa maemo a kotsi ho masea a sa tsoa tsoaloa le batho ba nang le boits'ireletso ba mmele bo fokolang. Leha meriana ea hajoale e thusa ho laola tšoaetso, kotsi ea ho hanyetsa meriana le litla-morao e ntse e le taba. Re hloka meriana e mecha ho lebisa kokoana-hloko hantle.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Ho na le mefuta e 'meli ea kokoana-hloko ea herpes simplex , mofuta oa 1 (HSV-1) le mofuta oa 2 (HSV-2). HSV-1 hangata e baka tšoaetso ho potoloha hanong ha HSV-2 hangata e baka mafu a litho tsa botona kapa botšehali. Li fetisoa ka ho kopana ka ho toba le motho ea tšoaelitsoeng. Genital herpes e khetholloa e le tšoaetso ea thobalano. E ka fetisetsoa ho lesea nakong ea pelehi. Ka mor'a tšoaetso, likokoana-hloko li tsamaisoa hammoho le methapo ea kutlo ho ea 'meleng oa lisele tsa methapo, moo li lulang bophelo bohle ba tsona. Lisosa tsa ho pheta-pheta li ka kenyelletsa: ho fokotseha ha ts'ebetso ea 'mele ea ho itšireletsa mafung, khatello ea maikutlo, le ho pepesehela letsatsi.
Maemong a mangata, lithethefatsi tse thibelang likokoana-hloko li nooa feela ha matšoao a le matla. Meriana ea letsatsi le letsatsi ea antiviral e ka fuoa motho ea nang le tšoaetso khafetsa. Ha ho na ente e fumanehang 'me ente ea shingles ha e thibele herpes simplex. Kalafo ka meriana e thibelang kokoana-hloko e kang aciclovir kapa valaciclovir e ka fokotsa ho teba ha matšoao.
Litefiso tsa lefatše ka bophara tsa HSV-1 kapa HSV-2 li pakeng tsa 60% le 95% ho batho ba baholo. HSV-1 hangata e tšoaetsoa nakong ea bongoana. Ho hakanngoa hore batho ba limilione tse 536 lefatšeng ka bophara (16% ea baahi) ba tšoaelitsoe ke HSV-2 ho tloha ka 2003 ka sekhahla se seholo har'a basali le ba linaheng tse tsoelang pele. Batho ba bangata ba nang le HSV-2 ha ba hlokomele hore ba na le tšoaetso.
○ Kalafo - Lithethefatsi tsa OTC
Qoba ho ama leha e le efe 'meleng, joalo ka ho aka ngoana, ha marako a ntse a le teng, kaha ho kopana ho ka fetisetsa tšoaetso ho batho ba bang. U lokela ho phomola ntle le ho noa joala.
#Acyclovir cream